Foundation Medicine  

150 Second Street
Cambridge,  MA  02141

United States
  • Booth: 13159

Foundation Medicine is a molecular information company dedicated to transforming cancer care where treatment is informed by a deep understanding of the genomic changes that contribute to each patient’s unique cancer. We offer a full suite of comprehensive genomic profiling assays to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies, immunotherapies and clinical trials. Our molecular information platform improves patient care by assisting clinicians, researchers and drug developers to advance the science of molecular medicine in cancer.


  • FoundationOne®
    FoundationOne® is the gold standard in comprehensive genomic profiling for solid tumors....

  • FoundationOne® is the gold standard in comprehensive genomic profiling for solid tumors. With its hybrid-capture, next-generation sequencing technology and deep bioinformatics and clinical pipeline, this rigorously validated assay:

    • Interrogates the entire coding sequence of 315 cancer-related genes plus select introns from 28 genes
    • Identifies all four alteration types (base substitutions, insertions and deletions, copy number alterations, and rearrangements)
    • Expands treatment options for your patients by matching each patient with targeted therapies and clinical trials that are relevant to the molecular changes in their tumor
    • Saves precious time and tissue with reported results in 11-14 days and  limited tissue required (50 ng of DNA from an FFPE block or 10 slides + H&E slide)
    • Helps you predict your patients’ potential immunotherapy response with:
      • Tumor Mutational Burden (TMB) in mutations per megabase (mut/MB)
      • Microsatellite Instability (MSI) 
  • FoundationACT™
    FoundationACT™ is Foundation Medicine’s hybrid-capture based liquid biopsy....

  • FoundationACT™ is Foundation Medicine’s hybrid-capture based liquid biopsy.  This carefully validated assay provides more options for more patients by:

    • Requiring a simple blood draw in place of a tissue biopsy
    • Interrogating the 62 most clinically-relevant genes commonly altered in late stage solid tumors
    • Detecting all four alteration types with high sensitivity and specificity (PPV)
    • Matching a patient’s alterations detected through tumor cells shed into the blood (ctDNA) with targeted therapies and clinical trials associated with the driving alterations